Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
Molecular Cancer Research : MCR
|
December 14, 2011
Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1
Gregory P Botta, Mauricio J Reginato, Maximilian Reichert, et al.
Nature Protocols
|
June 22, 2013
Isolation, culture and genetic manipulation of mouse pancreatic ductal cells
Maximilian Reichert, Shigetsugu Takano, Steffen Heeg, et al.
BMC Gastroenterology
|
September 4, 2021
Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC)
Safa Elzein, Fei Bao, Ray Lin, et al.
JCI Insight
|
August 10, 2021
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Gregory P Botta, Shumei Kato, Hitendra Patel, et al.
Neoplasia (New York, N.Y.)
|
April 5, 2013
ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells
Gregory P Botta, Maximilian Reichert, Mauricio J Reginato, et al.
Cancer Medicine
|
December 8, 2022
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients
Gregory P Botta, Tridu R Huynh, Samantha R Spierling-Bagsic, et al.
Cell Transplantation
|
June 16, 2009
Sex of muscle stem cells does not influence potency for cardiac cell therapy
Lauren Drowley, Masaho Okada, Thomas R Payne, et al.
NPJ Genomic Medicine
|
January 20, 2023
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Justin Shaya, Shumei Kato, Jacob J Adashek, et al.
Biomaterials
|
October 2, 2012
Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked with genipin for bone tissue engineering
Michael E Frohbergh, Anna Katsman, Gregory P Botta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 16, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations
Shawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
Molecular Cancer Research : MCR
|
December 14, 2011
Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1
Gregory P Botta, Mauricio J Reginato, Maximilian Reichert, et al.
Nature Protocols
|
June 22, 2013
Isolation, culture and genetic manipulation of mouse pancreatic ductal cells
Maximilian Reichert, Shigetsugu Takano, Steffen Heeg, et al.
BMC Gastroenterology
|
September 4, 2021
Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC)
Safa Elzein, Fei Bao, Ray Lin, et al.
JCI Insight
|
August 10, 2021
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Gregory P Botta, Shumei Kato, Hitendra Patel, et al.
Neoplasia (New York, N.Y.)
|
April 5, 2013
ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells
Gregory P Botta, Maximilian Reichert, Mauricio J Reginato, et al.
Cancer Medicine
|
December 8, 2022
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients
Gregory P Botta, Tridu R Huynh, Samantha R Spierling-Bagsic, et al.
Cell Transplantation
|
June 16, 2009
Sex of muscle stem cells does not influence potency for cardiac cell therapy
Lauren Drowley, Masaho Okada, Thomas R Payne, et al.
NPJ Genomic Medicine
|
January 20, 2023
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Justin Shaya, Shumei Kato, Jacob J Adashek, et al.
Biomaterials
|
October 2, 2012
Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked with genipin for bone tissue engineering
Michael E Frohbergh, Anna Katsman, Gregory P Botta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 16, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations
Shawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
Page
of 4